Tempest Therapeutics, Inc. (TPST) Form 8-K — Oct 19, 2026
$TPSTForm 8-KItems 5.02, 7.01, 9.01Filed Oct 19, 2026, 4:05 PM ET0001213900-26-110669Original filing
Tempest Therapeutics (TPST) appointed John W. Frederick to its board of directors effective October 13, 2026, serving as a Class III director until the 2027 annual meeting.
Key figures
- Term
- until 2027 annual meeting of stockholders
- Director class
- Class III
- Initial option award shares
- 25000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.